Trafficking of Gold Nanoparticles Coated with the 8D3 Anti-Transferrin Receptor Antibody at the Mouse Blood-Brain Barrier

dc.contributor.author
Cabezón Rodríguez, Itsaso
dc.contributor.author
Manich Raventós, Gemma
dc.contributor.author
Martín Venegas, Raquel
dc.contributor.author
Camins Espuny, Antoni
dc.contributor.author
Pelegrí i Gabaldà, Carme
dc.contributor.author
Vilaplana i Hortensi, Jordi
dc.date.issued
2020-07-23T08:04:28Z
dc.date.issued
2020-07-23T08:04:28Z
dc.date.issued
2015
dc.date.issued
2020-07-23T08:04:28Z
dc.identifier
1543-8384
dc.identifier
https://hdl.handle.net/2445/169368
dc.identifier
654709
dc.description.abstract
Receptor-mediated transcytosis has been widely studied as a possible strategy to transport neurotherapeutics across the blood-brain barrier (BBB). Monoclonal antibodies directed against the transferrin receptor (TfR) have been proposed as potential carrier candidates. A better understanding of the mechanisms involved in their cellular uptake and intracellular trafficking is required and could critically contribute to the improvement of delivery methods. Accordingly, we studied here the trafficking of gold nanoparticles (AuNPs) coated with the 8D3 anti-transferrin receptor antibody at the mouse BBB. 8D3-AuNPs were intravenously administered to mice and allowed to recirculate for a range of times, from 10 min to 24 h, before brain extraction and analysis by transmission electron microscope techniques. Our results indicated a TfR-mediated and clathrin-dependent internalization process by which 8D3-AuNPs internalize individually in vesicles. These vesicles then follow at least two different routes. On one hand, most vesicles enter intracellular processes of vesicular fusion and rearrangement in which the AuNPs end up accumulating in late endosomes, multivesicular bodies or lysosomes, which present a high AuNP content. On the other hand, a small percentage of the vesicles follow a different route in which they fuse with the abluminal membrane and open to the basal membrane. In these cases, the 8D3-AuNPs remain attached to the abluminal membrane, which suggests an endosomal escape, but not dissociation from TfR. Altogether, although receptor-mediated transport continues to be one of the most promising strategies to overcome the BBB, different optimization approaches need to be developed for efficient drug delivery. Keywords: blood−brain barrier; drug delivery; electron microscopy; monoclonal antibodies; receptor-mediated transport; transferrin receptor.
dc.format
9 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
American Chemical Society
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1021/acs.molpharmaceut.5b00597
dc.relation
Molecular Pharmaceutics, 2015, vol. 12, p. 4137-4145
dc.relation
https://doi.org/10.1021/acs.molpharmaceut.5b00597
dc.rights
(c) American Chemical Society , 2015
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Bioquímica i Fisiologia)
dc.subject
Nanopartícules
dc.subject
Barrera hematoencefàlica
dc.subject
Fisiologia animal
dc.subject
Nanoparticles
dc.subject
Blood-brain barrier
dc.subject
Animal physiology
dc.title
Trafficking of Gold Nanoparticles Coated with the 8D3 Anti-Transferrin Receptor Antibody at the Mouse Blood-Brain Barrier
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.